Australia's most trusted
source of pharma news
Posted 28 August 2025 PM
A combo of blockbusters has shown efficacy in a new indication, becoming the first regimen to improve survival for certain types of bladder cancer.
ADC Padcev, sponsored by Astellas in Australia, in combination with MSD's PD-1 inhibitor Keytruda, met the primary endpoint in the EV-303 phase 3 study as neoadjuvant and adjuvant treatment versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.